When most of us think of vaccines, we probably think of the vaccinations we received as children, the ones that left our arms sore, even days later. Vaccines have been used to successfully prevent diseases such as smallpox, measles, polio and other infectious diseases, for many years. But vaccines are not only for preventing infectious diseases;newer vaccines are providing protections against a wide array of other diseases, including cancer prevention.
Most Recent Posts
We can - and do - talk about the Alzheimer's disease: what it is and how you detect it. We can talk about what it means for patients and our economy if we don't find new treatments and a way to delay its onset.
Earlier today I came across the news that the venerable Levon Helm, singer and drummer for The Band and multi-Grammy award winner as a solo artist, is in the very late stages of his battle with cancer. I don't know about all of you, but I can't count how many times I've watched/listened to "The Last Waltz," mesmerized by the artistry and energy that Helm and his Band-mates brought to the stage.
Helm is an amazing talent, even after he lost and then regained his voice in earlier bouts with throat cancer.
Today has been a big day for reauthorization of the Prescription Drug User Fee Act - which, as a reminder, is legislation that must pass by the end of September at the latest.
We're viewing a new survey from the National Coalition on Healthcare (NCHC) with a healthy dose of skepticism. Not only do we not agree with the results, but we feel strongly that when discussing copay coupons, it's important to understand why they are necessary.
I recently worked with the American Cancer Society and some local biotech executives on the launch of a new report - Research in Your Backyard: Pharmaceutical Clinical Trials in Oregon. We all agreed that this report was a good start, but that more needed to be done to solve the largest challenge facing clinical trials today: educating patients about the importance of participation.
This is a guest post from John C. Lechleiter, PhD, who is Chairman, President and CEO of Eli Lilly and Company. Starting today, Mr. Lechleiter is also the Chairman of the Board of Directors of PhRMA.
Today, Americans are plugged into a constant stream of news and information like never before in history, yet many patients are still struggling to remain informed on their basic healthcare needs. Adele Gulfo, President and General Manager of U.S. Primary Care for Pfizer, makes the case that more must be done to build a direct dialogue with patients and encourage healthcare compliance. Listen to Adele discuss the vast opportunities we should tap into in order to break barriers and proactively reach patients to improve health outcomes.
Listen as healthcare consultant Ron Williams shares his message of ensuring the U.S. healthcare systems does a better job of managing the health of the population. While it is important to be able to effectively diagnose and treat illnesses, the treatments are only as successful as the patient's ability and willingness to receive them. Mr. Williams outlines how patients can avoid the progression of their illnesses into a more serious chronic disease by better understanding their role in complying with their advised medical regiment.
The benefits of medical innovation span far beyond improving patient outcomes and stemming healthcare costs. Research and development spurs jobs and injects much-needed capital back into the economy as Americans build and maintain new facilities from the ground up.
Mellanie T. Hills is a heart disease survivor, heart health expert, patient advocate, award-winning author, and founder and CEO of the non-profit American Foundation for Women's Health and StopAfib.org, an atrial fibrillation patient advocacy organization. Atrial Fibrillation is the most common irregular heart beat that causes strokes in 1.7 million people each year, but the root cause has not been identified. Listen to Mellanie discuss this devastating condition and the need for raising awareness and discovering the cause.
The U.S. is a global leader in medical research and development, but is that leadership role at risk? James Capretta, a Fellow at the Ethics and Public Policy Center (EPPC) focuses on public policy and economic issues with a focus on health-care and entitlement reform and previously served as an Associate Director at the White House Office of Management and Budget (OMB). Listen to what he worries could jeopardize our country's competitive advantage in medical innovation.
New PhRMA Chairman John Lechleiter, President and CEO of Eli Lilly and Company, continued the vein of optimism in his comments this morning. He urged those of us in the room "to stand up for policies that support innovation, to continue to build trust with our stakeholders, and to get our powerful story out."
We must do so, he said, to continue the "heroic work of healing and saving lives well into the future."
In their moderated discussion this morning, outgoing PhRMA Chairman Christopher Viehbacher (from Sanofi) and incoming PhRMA Chairman John Lechleiter (from Eli Lilly and Company) discussed ways that companies can maximize different types of opportunities.
Today we have a guest post from Samir Khalil, the executive director of public policy for Merck's Asia Pacific & China region. At PhRMA's Annual Meeting he participated in a panel discussion on healthcare trends in emerging markets.